Cancer & Disease Research
What's next for cellular immunotherapies?
CARLSBAD, CA - What's the next step in the development of cellular immunotherapies, particularly for liquid and solid tumors? At this week's Cell & Gene Meeting on the Mesa, Dr. Kanya Rajangam, PhD, of Nkarta Therapeutics explained the latest approaches. Read More
Tecartus becomes 1st CAR T-cell therapy to receive FDA approval for adults with ALL
Tecartus (brexucabtagene autoleucel), a CAR T-cell therapy, has gained approval from the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adult patients. Read More
How one company aims to make bedside cell therapies a reality
SQZ Biotech is developing high-throughput technology that can manufacture novel cell therapy products in under 24 hours. Founder and CEO Armon Sharei, PhD, spoke with ScienceBoard.net recently at Biotech Week Boston 2021. Read More
End-to-end automation of closed manufacturing can make cell therapies more accessible
BOSTON - Cellares is building a cell manufacturing platform that fully automates and closes the process, according to co-founder and CEO Fabian Gerlinghaus. ScienceBoard.net spoke with Gerlinghaus following a presentation at the Cell and Gene Manufacturing and Commercialization event, which is part of Biotech Week Boston 2021. Read More
Biotech Week Boston highlights research progress in cell and gene therapy
At Biotech Week Boston, ScienceBoard.net Editor-in-Chief Samantha Black, PhD, spoke with experts in cell and gene therapy technologies. Read More
New gene therapy platform shows potential against certain muscle diseases
Scientists have engineered a new family of adeno-associated viruses (AAVs) to deliver therapeutic genes to muscle tissue at 100 to 250 times lower doses than previous AAV vectors, potentially reducing the risk of liver damage and other serious side effects, according to a new study published in Cell on September 9. Read More
KromaTiD launches mapping service for human genome in single cells
KromaTiD has launched a new product called dGH Screen for mapping the human genome in single cells. The tool uses the company's proprietary directional genomic hybridization (dGH) technology, a platform for measuring genomic structure and structural variation. Read More
Cell and gene therapy firms see over $13.6B so far in 2021
Rapid financing activity in the cell and gene therapy industry has exceeded $13 billion in 2021. Over half of this funding is from venture capital and private investments, with over 100 funding deals of this type. Read More
Heat-controlled CAR T cells show improved cancer-killing ability
By adding a genetic on-off switch to engineered CAR T cells, researchers have developed a remote-controlled system that enables precision invasion of the tumor microenvironment for improved cancer-killing capabilities. The details of the research were published in Nature Biomedical Engineering on August 12. Read More
Cellular programming spurs next-generation cell therapies
Cellular reprogramming of ex vivo cells may offer improvements on first-generation adoptive cell therapies, which have experienced limited clinical success due to complex manufacturing, potential patient rejection, and availability of clinical cell types. Further, in vivo reprogramming may expand on this concept by eliminating the need for manufacture and the risk of immune rejection. Read More
Conferences
Cell Bio 2021
December 11-15
San Diego, California United States
Antibody Engineering and Therapeutics
December 13-17
San Diego, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter